| SKU | Size | Availability | Price | Qty |
|---|---|---|---|---|
| Ab175611-100μg | 100μg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $39.90 | |
| Ab175611-1mg | 1mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $199.90 | |
| Ab175611-5mg | 5mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $489.90 | |
| Ab175611-10mg | 10mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $709.90 |
Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG4; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
| Product Name | Natalizumab (anti-ITGA4) - Primary antibody, specific to ITGA4, Human IgG4 |
|---|---|
| Synonyms | 269C wild type antibody | Antigen CD49D, alpha 4 subunit of VLA 4 receptor antibody | CD49 antigen like family member D antibody | CD49 antigen-like family member D antibody | CD49d antibody | IA4 antibody | Integrin alpha 4 antibody | Integrin alpha 4 su |
| Specifications & Purity | ExactAb™, Validated, Carrier Free, Low Endotoxin, Azide Free, Recombinant, ≥95%(SDS-PAGE&SEC), Lot by Lot |
| Host species | Human |
| Specificity | ITGA4 |
| Conjugation | Unconjugated |
| Grade | Azide Free, Carrier Free, ExactAb™, Low Endotoxin, Recombinant, Validated |
| Action Type | INHIBITOR |
| Mechanism of action | Antibody of integrin α4β1;Antibody of integrin; alpha 4 subunit (antigen CD49D; alpha 4 subunit of VLA-4 receptor) |
| Product Description | Natalizumab (anti-ITGA4) is a recombinant, humanized IgG4 monoclonal antibody, binds to α4β1-integrin and blocks its interaction with vascular cell adhesion molecule-1 (VCAM-1). Natalizumab (anti-ITGA4) can be used for the treatment of relapsing remitting multiple sclerosis and Crohn's disease. Natalizumab (anti-ITGA4) is also the first targeted therapy which blocks an essential mechanism for lymphocyte entry to the CNS and thus prevents acute demyelinating relapses. |
| Isotype | Human IgG4 |
|---|---|
| Light Chain Type | kappa |
| SDS-PAGE | 26.1 kDa (Light Chain) & 51.3 kDa (Heavy Chain), under reducing conditions; 192.7 kDa, under non-reducing conditions. |
| Purification Method | Protein A purified |
| Form | Liquid |
| Concentration | Lot by Lot |
| Storage Temp | Store at -80°C,Avoid repeated freezing and thawing |
| Shipped In | Ice chest + Ice pads |
| Stability And Storage | Store at -80℃ for 24 months. Upon delivery aliquot. Avoid freeze/thaw cycle. |
| CAS | 189261-10-7 |
Natalizumab (anti-ITGA4) (Ab175611) - Flow Cytometry
Flow Cytometry analysis of Jurkat cells labelling ITGA4 (red) with Natalizumab (anti-ITGA4) (Ab175611). Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.
Natalizumab (anti-ITGA4) (Ab175611) - SEC
The purity of Natalizumab (anti-ITGA4) (Ab175611) is more than 95% verified by HPLC.
Natalizumab (anti-ITGA4) (Ab175611) - Flow Cytometry
Flow Cytometry analysis of Raji cells labelling ITGA4 (red) with Natalizumab (anti-ITGA4) (Ab175611). Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.
Natalizumab (anti-ITGA4) (Ab175611) - Flow Cytometry
Flow Cytometry analysis of U937 cells labelling ITGA4 (red) with Natalizumab (anti-ITGA4) (Ab175611). Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.
Natalizumab (anti-ITGA4) (Ab175611) - Flow Cytometry
Flow Cytometry analysis of HeLa cells labelling ITGA4 (red) with Natalizumab (anti-ITGA4) (Ab175611). Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
| IMGT/mAb-DB | 75 |
|---|---|
| Wikipedia | Natalizumab |
| PEP | natalizumab |
| Reactome Reaction | R-HSA-9679740 |
| Reactome Drug | R-ALL-9679737 |
Enter Lot Number to search for COA:
Find and download the COA for your product by matching the lot number on the packaging.
| Lot Number | Certificate Type | Date | Item |
|---|---|---|---|
 ZJ24F0606633 | Certificate of Analysis | Jun 07, 2024 | Ab175611 |
| ZJ24F0606632 | Certificate of Analysis | Jun 07, 2024 | Ab175611 |
| ZJ24F0606631 | Certificate of Analysis | Jun 07, 2024 | Ab175611 |
| 1. Mackay CR. (2008) Moving targets: cell migration inhibitors as new anti-inflammatory therapies.. Nat Immunol, 9 (9): (988-98). [PMID:18711436] |
| 2. Léger OJ, Yednock TA, Tanner L, Horner HC, Hines DK, Keen S, Saldanha J, Jones ST, Fritz LC, Bendig MM. (1997) Humanization of a mouse antibody against human alpha-4 integrin: a potential therapeutic for the treatment of multiple sclerosis.. Hum Antibodies, 8 (1): (3-16). [PMID:9265500] |
